Gastroscreen with stimulation

A complex blood test including specific digestive tract proteins (gastrin-17, pepsinogen I and II) and IgG antibodies to H. pylori, which is used for non-invasive assessment of the state of the gastric mucosa and the state of secretory activity of the gastric mucosa. It allows gaining insight into the level of hydrochloric acid secretion, establishing the nature and severity of changes in the gastric mucosa, as well as the fact of Helicobacter pylori infection – the main cause of chronic gastritis, gastric ulcer disease, and gastric cancer.

Blood sampling is performed 2 times: on an empty stomach and 20 minutes after protein stimulation. The level of gastrin-17 in blood taken after a 6-8 hour fasting period, and in the sample after protein stimulation allows for a clearer determination of increased hydrochloric acid secretion and atrophic changes in the antral part of the gastric mucosa.

Information about protein load before taking the test

Important! Stimulation is provided by intake of high-protein food or a high-protein drink after fasting for at least 4-10 hours. It is necessary to bring high-protein food/drink with you. 20 minutes after protein stimulation, blood is drawn again to assess the change in the level of stimulated gastrin-17 compared to the fasting level.

"Gastroscreen" is based on the assessment of the interaction of four key biomarkers regulating normal gastric physiology:

• pepsinogen I;
• pepsinogen II;
• gastrin-17;
• IgG antibodies to Helicobacter pylori (quantitative).

Method advantages:
• non-invasive method for diagnosing gastric pathology when there are contraindications to instrumental examination methods (EGD, etc.);
• allows diagnosing and developing a treatment strategy for atrophic gastritis (including H. pylori etiology);
• possibility of repeated examination in dynamics to monitor therapy effectiveness.

Indications for the study
Diagnosis of the condition and localization of changes in the gastric mucosa:
• with clinical and laboratory signs of gastritis of the antral part of the stomach, with suspicion of the presence of precancerous changes in the stomach with gastritis (atrophy, intestinal metaplasia) to confirm the diagnosis, assess the risk of developing gastric cancer and determine the procedure for endoscopic observation);
• in patients with contraindications to endoscopic examination;
• presence of relatives with gastric cancer or chronic atrophic gastritis;
• with iron deficiency and pernicious anemia;
• with dyspepsia;
• to monitor therapy with proton pump inhibitors (PPIs).

Within 4 days